Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Resource Type
Article
Authors
Soumerai, Jacob D ; Mato, Anthony R ; Dogan, Ahmet ; Seshan, Venkatraman E ; Joffe, Erel ; Flaherty, Kelsey ; Carter, Jason ; Hochberg, Ephraim ; Barnes, Jeffrey A ; Hamilton, Audrey M ; Abramson, Jeremy S ; Batlevi, Connie L ; Matasar, Matthew J ; Noy, Ariela ; Owens, Colette N ; Palomba, M Lia ; Kumar, Anita ; Takvorian, Tak ; Ni, Ai ; Choma, Morgan ; Friedman, Chaya ; Chadha, Puja ; Simkins, Elizabeth ; Ruiters, Jade ; Sechio, Sidney ; Portman, Daneal ; Ramos, Lauren ; Nolet, Natascha ; Mahajan, Neena ; Martignetti, Rosalba ; Mi, Joanna ; Scorsune, Krista ; Lynch, Julia ; McGree, Brianne ; Hughes, Stephanie ; Grieve, Clare ; Roeker, Lindsey E ; Thompson, Meghan ; Johnson, P Connor ; Roshal, Mikhail ; Huang, Jane ; Biondo, Juliana ; Wu, Qun ; Jacob, Allison ; Abdel-Wahab, Omar ; Zelenetz, Andrew D
Source
In The Lancet Haematology December 2021 8(12):e879-e890
Subject
Primary Research Articles
Language
ISSN
2352-3026